Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors

Mycosis fungoides (MF) and Sézary syndrome (SS) are forms of cutaneous T cell lymphoma (CTCL) that pose significant challenges in their clinical management, particularly in refractory and advanced-stage disease. With the emergence of novel therapeutic modalities however, there are increasing opportu...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 14; p. 1291259
Main Authors Quadri, Iman, Reneau, John C, Hanel, Walter, Chung, Catherine G
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 2023
Subjects
Antibodies, Monoclonal - therapeutic use
cancer therapeutics
cutaneous T-cell lymphoma
Humans
immune checkpoint inhibitors
Immunotherapy
Janus Kinase Inhibitors
Lymphoma, T-Cell, Cutaneous
mycosis fungoides
Mycosis Fungoides - drug therapy
Sezary Syndrome - drug therapy
Skin Neoplasms - drug therapy
Sézary syndrome
cutaneous T-cell lymphoma
immunotherapy
cancer therapeutics
immune checkpoint inhibitors
Sézary syndrome
Janus kinus inhibitors
mycosis fungoides
monoclonal antibodies
Online AccessGet full text

Cover

More Information
Summary:Mycosis fungoides (MF) and Sézary syndrome (SS) are forms of cutaneous T cell lymphoma (CTCL) that pose significant challenges in their clinical management, particularly in refractory and advanced-stage disease. With the emergence of novel therapeutic modalities however, there are increasing opportunities to exploit the current understanding of pathophysiologic mechanisms of MF/SS for treatment. This review summarizes recent advances in the treatment of MF/SS, with a focus on monoclonal antibodies, immunotherapies, and Janus kinase (JAK) inhibitors, including ongoing clinical trials.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1291259